Insider Selling: Albireo Pharma, Inc. (NASDAQ:ALBO) Insider Sells 938 Shares of Stock

Albireo Pharma, Inc. (NASDAQ:ALBO – Get Rating) insider Martha J. Carter sold 938 shares of the business’s stock in a transaction dated Thursday, January 19th. The stock was sold at an average price of $43.90, for a total transaction of $41,178.20. Following the transaction, the insider now owns 14,626 shares in the company, valued at $642,081.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Albireo Pharma Stock Performance

Shares of ALBO stock opened at $43.81 on Monday. The firm’s 50 day moving average price is $25.87 and its 200-day moving average price is $22.52. Albireo Pharma, Inc. has a one year low of $16.02 and a one year high of $44.40. The firm has a market cap of $906.91 million, a P/E ratio of -6.52 and a beta of 0.81.

Albireo Pharma (NASDAQ:ALBO – Get Rating) last issued its quarterly earnings data on Tuesday, November 8th. The biopharmaceutical company reported ($1.89) EPS for the quarter, missing the consensus estimate of ($1.86) by ($0.03). Albireo Pharma had a negative return on equity of 97.13% and a negative net margin of 228.51%. The company had revenue of $9.83 million during the quarter, compared to analyst estimates of $9.68 million. As a group, research analysts predict that Albireo Pharma, Inc. will post -7.86 EPS for the current fiscal year.

Hedge Funds Weigh In On Albireo Pharma

Several large investors have recently made changes to their positions in the stock. Chicago Capital LLC increased its stake in Albireo Pharma by 21.7% during the 4th quarter. Chicago Capital LLC now owns 1,362,484 shares of the biopharmaceutical company’s stock worth $29,443,000 after buying an additional 242,710 shares during the period. Birchview Capital LP increased its stake in Albireo Pharma by 3.5% during the 3rd quarter. Birchview Capital LP now owns 117,000 shares of the biopharmaceutical company’s stock worth $2,265,000 after buying an additional 4,000 shares during the period. M&T Bank Corp increased its stake in Albireo Pharma by 17.0% during the 3rd quarter. M&T Bank Corp now owns 24,962 shares of the biopharmaceutical company’s stock worth $484,000 after buying an additional 3,632 shares during the period. Jane Street Group LLC increased its stake in Albireo Pharma by 152.7% during the 3rd quarter. Jane Street Group LLC now owns 61,652 shares of the biopharmaceutical company’s stock worth $1,194,000 after buying an additional 37,252 shares during the period. Finally, BNP Paribas Arbitrage SNC increased its stake in Albireo Pharma by 112.9% during the 3rd quarter. BNP Paribas Arbitrage SNC now owns 13,840 shares of the biopharmaceutical company’s stock worth $268,000 after buying an additional 7,338 shares during the period. 94.25% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on ALBO shares. Cowen lowered shares of Albireo Pharma from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $68.00 to $48.00 in a research report on Wednesday, January 11th. StockNews.com started coverage on shares of Albireo Pharma in a report on Wednesday, October 12th. They issued a “sell” rating on the stock. Guggenheim lowered shares of Albireo Pharma from a “buy” rating to a “neutral” rating in a report on Wednesday, January 11th. Robert W. Baird boosted their target price on shares of Albireo Pharma from $43.00 to $55.00 and gave the company an “outperform” rating in a report on Wednesday, October 12th. Finally, Jefferies Financial Group lowered shares of Albireo Pharma from a “buy” rating to a “hold” rating and decreased their target price for the company from $49.00 to $42.00 in a report on Wednesday, January 11th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $48.00.

About Albireo Pharma

(Get Rating)

Albireo Pharma, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases.